Pfizer cuts 2022 earnings outlook even as Q1 sales rise

The US company's first-quarter revenues surged 77% to over $25bn compared to the same period last year, driven by $13.2bn in Covid vaccine sales. However, Pfizer has downgraded its profit guidance for the year amid rising research and development costs.

Read the full article.